Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $20

Author: Benzinga Newsdesk | July 08, 2025 08:02am
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $50 to $20.

Posted In: JSPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist